A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
PHASE1
This multicenter, open-label, Phase I study will evaluate the safety, effic...
The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID
N/A
Hong Kong is a region of intermediate TB burden, and the reactivation of la...
Status
Completed
Location
Prince of Wales Hospital
Start Date
2012-03
Trial ID
NCT02135289
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
PHASE3
The purpose of this study is to evaluate how well JNJ-79635322 works when c...